Skip to content
RDL Network logo
1095P Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial — Alexander M.M. Eggermont (2024) | RDL Network